Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 2191

Related Citations for PubMed (Select 17391739)

1.

Response-driven combination therapy with conventional disease-modifying antirheumatic drugs can achieve high response rates in early rheumatoid arthritis with minimal glucocorticoid and nonsteroidal anti-inflammatory drug use.

Proudman SM, Keen HI, Stamp LK, Lee AT, Goldblatt F, Ayres OC, Rischmueller M, James MJ, Hill CL, Caughey GE, Cleland LG.

Semin Arthritis Rheum. 2007 Oct;37(2):99-111. Epub 2007 Mar 27.

PMID:
17391739
2.

The good initial response to therapy with a combination of traditional disease-modifying antirheumatic drugs is sustained over time: the eleven-year results of the Finnish rheumatoid arthritis combination therapy trial.

Rantalaiho V, Korpela M, Hannonen P, Kautiainen H, Järvenpää S, Leirisalo-Repo M, Hakala M, Puolakka K, Julkunen H, Luosujärvi R, Möttönen T; FIN-RACo Trial Group.

Arthritis Rheum. 2009 May;60(5):1222-31. doi: 10.1002/art.24447.

3.

Triple therapy in early active rheumatoid arthritis: a randomized, single-blind, controlled trial comparing step-up and parallel treatment strategies.

Saunders SA, Capell HA, Stirling A, Vallance R, Kincaid W, McMahon AD, Porter DR.

Arthritis Rheum. 2008 May;58(5):1310-7. doi: 10.1002/art.23449.

4.

Aggressive combination therapy with intra-articular glucocorticoid injections and conventional disease-modifying anti-rheumatic drugs in early rheumatoid arthritis: second-year clinical and radiographic results from the CIMESTRA study.

Hetland ML, Stengaard-Pedersen K, Junker P, Lottenburger T, Hansen I, Andersen LS, Tarp U, Svendsen A, Pedersen JK, Skjødt H, Lauridsen UB, Ellingsen T, Hansen GV, Lindegaard H, Vestergaard A, Jurik AG, Østergaard M, Hørslev-Petersen K; CIMESTRA study group.

Ann Rheum Dis. 2008 Jun;67(6):815-22. Epub 2007 Sep 18.

PMID:
17878209
5.

Low-dose prednisolone in rheumatoid arthritis: adverse effects of various disease modifying antirheumatic drugs.

Malysheva OA, Wahle M, Wagner U, Pierer M, Arnold S, Häntzschel H, Baerwald CG.

J Rheumatol. 2008 Jun;35(6):979-85. Epub 2008 Apr 15.

PMID:
18412314
7.

Aiming at low disease activity in rheumatoid arthritis with initial combination therapy or initial monotherapy strategies: the BeSt study.

Allaart CF, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Breedveld FC, Dijkmans BA; FARR study group.

Clin Exp Rheumatol. 2006 Nov-Dec;24(6 Suppl 43):S-77-82.

PMID:
17083767
8.

Delay to institution of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis.

Möttönen T, Hannonen P, Korpela M, Nissilä M, Kautiainen H, Ilonen J, Laasonen L, Kaipiainen-Seppänen O, Franzen P, Helve T, Koski J, Gripenberg-Gahmberg M, Myllykangas-Luosujärvi R, Leirisalo-Repo M; FIN-RACo Trial Group. FINnish Rheumatoid Arthritis Combination therapy.

Arthritis Rheum. 2002 Apr;46(4):894-8.

PMID:
11953964
9.

Prognostic markers of clinical remission in early rheumatoid arthritis after two years of DMARDs in a clinical setting.

Vázquez I, Graell E, Gratacós J, Cañete JD, Viñas O, Ercilla MG, Gómez A, Hernández MV, Rodríguez-Cros JR, Larrosa M, Sanmartí R.

Clin Exp Rheumatol. 2007 Mar-Apr;25(2):231-8.

PMID:
17543147
10.

Efficacy of triple DMARD therapy in patients with RA with suboptimal response to methotrexate.

O'Dell JR, Haire C, Erikson N, Drymalski W, Palmer W, Maloley P, Klassen LW, Wees S, Moore GF.

J Rheumatol Suppl. 1996 Mar;44:72-4.

PMID:
8833058
11.

Prognostic factors of radiographic progression in early rheumatoid arthritis: a two year prospective study after a structured therapeutic strategy using DMARDs and very low doses of glucocorticoids.

Sanmartí R, Gómez-Centeno A, Ercilla G, Larrosa M, Viñas O, Vazquez I, Gómez-Puerta JA, Gratacós J, Salvador G, Cañete JD.

Clin Rheumatol. 2007 Jul;26(7):1111-8. Epub 2006 Nov 16.

PMID:
17109060
12.

Prognostic factors in a large cohort of patients with early undifferentiated inflammatory arthritis after application of a structured management protocol.

Quinn MA, Green MJ, Marzo-Ortega H, Proudman S, Karim Z, Wakefield RJ, Conaghan PG, Emery P.

Arthritis Rheum. 2003 Nov;48(11):3039-45.

13.

Common polymorphisms in the folate pathway predict efficacy of combination regimens containing methotrexate and sulfasalazine in early rheumatoid arthritis.

James HM, Gillis D, Hissaria P, Lester S, Somogyi AA, Cleland LG, Proudman SM.

J Rheumatol. 2008 Apr;35(4):562-71. Epub 2008 Mar 1.

PMID:
18322994
14.

Disability measured by the modified health assessment questionnaire in early rheumatoid arthritis: prognostic factors after two years of follow-up.

Graell E, Vazquez I, Larrosa M, Rodríguez-Cros JR, Hernández MV, Gratacós J, Gómez A, Cañete JD, Gómez-Puerta JA, Sanmartí R.

Clin Exp Rheumatol. 2009 Mar-Apr;27(2):284-91.

PMID:
19473570
15.

Early suppression of disease activity is essential for maintenance of work capacity in patients with recent-onset rheumatoid arthritis: five-year experience from the FIN-RACo trial.

Puolakka K, Kautiainen H, Möttönen T, Hannonen P, Korpela M, Hakala M, Järvinen P, Ahonen J, Forsberg S, Leirisalo-Repo M; FIN-RACo Trial Group.

Arthritis Rheum. 2005 Jan;52(1):36-41.

16.

Retardation of joint damage in patients with early rheumatoid arthritis by initial aggressive treatment with disease-modifying antirheumatic drugs: five-year experience from the FIN-RACo study.

Korpela M, Laasonen L, Hannonen P, Kautiainen H, Leirisalo-Repo M, Hakala M, Paimela L, Blåfield H, Puolakka K, Möttönen T; FIN-RACo Trial Group.

Arthritis Rheum. 2004 Jul;50(7):2072-81.

17.

Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group.

Möttönen T, Hannonen P, Leirisalo-Repo M, Nissilä M, Kautiainen H, Korpela M, Laasonen L, Julkunen H, Luukkainen R, Vuori K, Paimela L, Blåfield H, Hakala M, Ilva K, Yli-Kerttula U, Puolakka K, Järvinen P, Hakola M, Piirainen H, Ahonen J, Pälvimäki I, Forsberg S, Koota K, Friman C.

Lancet. 1999 May 8;353(9164):1568-73.

PMID:
10334255
18.

Rituximab therapy in patients with rheumatoid arthritis refractory or with contraindication to anti-tumour necrosis factor drugs: real-life experience in Finnish patients.

Valleala H, Korpela M, Möttönen T, Hienonen-Kempas T, Kauppi M, Hannonen P, Leirisalo-Repo M.

Scand J Rheumatol. 2009;38(5):323-7. doi: 10.1080/03009740902946355.

PMID:
19585384
19.

Treatment of early RA in clinical practice: a comparative study of two different DMARD/corticosteroid options.

Svensson B, Ahlmén M, Forslind K.

Clin Exp Rheumatol. 2003 May-Jun;21(3):327-32.

PMID:
12846051
20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk